Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIOVAN HCT vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Valsartan is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor, causing vasodilation and reduced aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule, increasing excretion of sodium and water.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension (FDA-approved),Heart failure (off-label, valsartan component),Post-myocardial infarction (off-label, valsartan component)
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
One tablet orally once daily. Available strengths: 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, 320 mg/25 mg. Titrate to blood pressure response; maximum dose 320 mg/25 mg daily.
250 mg orally twice daily
Valsartan: 6 hours; hydrochlorothiazide: 6–15 hours (mean 9.6 hours). Clinical context: allows once-daily dosing; half-life prolonged in renal impairment.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Valsartan is primarily metabolized by CYP2C9 (minor) and eliminated unchanged in bile and urine. Hydrochlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Valsartan: primarily biliary (83%) and renal (13%) as unchanged drug; hydrochlorothiazide: renal (≥95%) as unchanged drug.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Valsartan: 94–97% (primarily albumin); hydrochlorothiazide: 68% (albumin).
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Valsartan: 17 L (≈0.24 L/kg for 70 kg); hydrochlorothiazide: 3.6–7.8 L/kg (≈0.5–1.1 L/kg). Clinical meaning: Valsartan distributes mainly in plasma; HCTZ widely distributed into tissues.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Valsartan: 25% (oral, with food reduces absorption by 40%); hydrochlorothiazide: 65–75% (oral).
70-90% (oral); 100% (IV).
Contraindicated in anuria. For GFR 30-60 m L/min, use cautiously; consider lower starting doses. GFR <30 m L/min: not recommended due to thiazide component.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: no adjustment. Child-Pugh B: use caution; valsartan exposure increases significantly. Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not approved for pediatric patients; safety and efficacy not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
No initial dose adjustment required, but consider lower starting doses due to greater sensitivity to antihypertensive effects; monitor renal function and electrolytes.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Fetal toxicity: avoid use during pregnancy; can cause oligohydramnios and fetal renal dysfunction.,Hypotension in volume-depleted patients.,Electrolyte imbalances (e.g., hypokalemia, hyponatremia) due to thiazide component.,Renal impairment: monitor renal function; may exacerbate in bilateral renal artery stenosis.,Acute angle-closure glaucoma (thiazide component).,Sulfonamide allergy (cross-reactivity with thiazide).,Exacerbation of lupus erythematosus.
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Anuria,Hypersensitivity to valsartan, hydrochlorothiazide, or sulfonamide-derived drugs,Pregnancy (second and third trimesters),Severe hepatic impairment (Child-Pugh class C),Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (GFR <60 m L/min)
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid grapefruit juice as it may alter drug metabolism. Limit high-potassium foods (e.g., bananas, oranges, potatoes, spinach) if potassium levels rise. Reduce sodium intake (less than 2 g/day) to enhance antihypertensive effect. Avoid excessive alcohol consumption. Maintain adequate fluid intake to prevent dehydration.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
First trimester: Potential risk based on mechanism (angiotensin II receptor blockade and thiazide diuretic); second and third trimesters: Known fetal toxicity including oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal hypotension; avoid in pregnancy, especially after 20 weeks gestation.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
The active metabolites hydrochlorothiazide is excreted in low amounts in breast milk; low M/P ratio of approximately 0.25; valsartan excretion unknown; because of potential adverse effects on the nursing infant, especially renal effects, use is not recommended; alternative therapies are preferred.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
Dose adjustments are not applicable as DIOVAN HCT is contraindicated in pregnancy; exposure should be avoided; if required, consider switching to an alternative antihypertensive with a safer profile during pregnancy.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Diovan HCT combines valsartan (ARB) and hydrochlorothiazide (thiazide diuretic). Monitor renal function, electrolytes (especially potassium and sodium), and blood pressure. Avoid use in pregnancy; contraindicated in anuria and severe renal impairment. Use caution in patients with pre-existing electrolyte imbalances, diabetes, or history of gout. May cause hyperkalemia with valsartan and hypokalemia with HCTZ; net effect requires monitoring. Onset of action within 2 hours, peak effect at 4-6 hours. Not recommended for initial therapy; titrate from individual components.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take exactly as prescribed, usually once daily. Do not skip doses.,Avoid potassium supplements or salt substitutes without doctor approval.,Report symptoms of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, excessive thirst.,May cause dizziness or lightheadedness; avoid driving until you know how it affects you.,This medication can make you urinate more frequently; take in the morning to minimize nighttime urination.,Avoid alcohol, which can increase dizziness and blood pressure lowering effects.,Notify your doctor if you become pregnant or plan to become pregnant; this drug can harm the fetus.,Stay hydrated, especially in hot weather or during exercise, to prevent dehydration.,Tell your doctor about all other medications, especially NSAIDs, lithium, and other blood pressure drugs.,Do not stop taking without consulting your doctor; sudden discontinuation may worsen blood pressure.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIOVAN HCT vs ALDOCLOR-250, answered by our medical review team.
DIOVAN HCT is a Antihypertensive Combination that works by Valsartan is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor, causing vasodilation and reduced aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule, increasing excretion of sodium and water.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIOVAN HCT and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIOVAN HCT is: One tablet orally once daily. Available strengths: 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, 320 mg/25 mg. Titrate to blood pressure response; maximum dose 320 mg/25 mg daily.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIOVAN HCT and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIOVAN HCT is classified as Category C. First trimester: Potential risk based on mechanism (angiotensin II receptor blockade and thiazide diuretic); second and third trimesters: Known fetal toxicity including oligohydram. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.